Navigation Links
Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
Date:5/12/2008

ng process scale-up efforts, increased personnel related costs to support these efforts, and increased share-based compensation costs.

On January 1, 2006, Alexza adopted FAS 123R and reports employee share-based compensation expense based on the fair value of the award. Share-based compensation was $1,191,000 in the first quarter of 2008 compared to $719,000 in the comparable period in 2007.

Alexza's Consolidated Statements of Operations include the operations of Symphony Allegro, Inc., its variable interest entity. As the Company has no direct ownership in Allegro, it reduces its net loss by the losses incurred by Allegro. "Loss attributed to noncontrolling interest in Symphony Allegro, Inc." reduced net loss for the first quarter of 2008 by $3.8 million and reduced net loss for the first quarter of 2007 by $2.1 million.

Product Candidates Development Update

-- AZ-004 (Staccato loxapine). Alexza is developing AZ-004 for the

treatment of acute agitation in patients with schizophrenia or bipolar

disorder. In February 2008, Alexza initiated its first Phase 3

clinical trial, designed to enroll approximately 300 schizophrenic

patients with acute agitation at 25 U.S. clinical centers. The trial

is an in-clinic, multi-center, randomized, double-blind,

placebo-controlled study and will test AZ-004 at two dose levels, 5

and 10 mg. Patients may receive up to 3 doses of study drug in a

24-hour period, depending on their clinical status. The primary

endpoint for the study is the change from baseline in the PEC score,

measured at 2 hours after the first dose. Various assessments of a

patient's agitation state will be conducted at serial time points

using standard agitation scales over the first 4-hour post-dose time

period, with follow-up assessments at the end of the 24-hour study

period. Side effe
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
2. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
3. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
4. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
5. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
6. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
7. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
8. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
9. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
10. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
11. MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, ... announced the closing of an underwritten public offering of 3,500,000 ... an aggregate 3,500,000 shares of common stock, at an offering ... warrants have a per share exercise price of $5.00, are ...
(Date:12/24/2014)... “Preparative & Process Chromatography Market by Instrument ... Buffers, Valves, Guages, Seals), Accessories, Services, End User ... 2019” provides a detailed overview of the major ... strategies impacting the preparative and process chromatography market ...
(Date:12/24/2014)... SoundConnect’s 2015 next generation ... communication technology, provide continued education and inform users ... demonstrates online communication features and benefits; empowering users ... innovative and powerful tools. , According to SoundConnect’s ...
(Date:12/24/2014)... Texas (PRWEB) December 23, 2014 ... such as its definition, classification, application and industry ... process, and product cost structure. Production is separated ... covers upstream raw materials, equipment, downstream client survey, ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... Inc. (Nasdaq:,MITI), a biopharmaceutical company focusing on the ... and autoimmune,diseases, today announced that Dr. Christian Itin, ... part of a panel discussion titled,"Delivering On The ... 2007,RBC Capital Markets Healthcare Conference in New York, ...
... Dec. 5 Nastech Pharmaceutical,Company Inc. (Nasdaq: NSTK ... study with an undisclosed global leader in the production ... Factor IX protein,which is currently administered by injection to ... "We look forward to working with our new global ...
... RICHMOND, Calif., Dec. 4 Sangamo BioSciences,Inc. (Nasdaq: ... the,financial community on its latest developments in several of ... annual,Investor and Analyst Briefing that will be held from ... The presentation will be webcast live and may ...
Cached Biology Technology:Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007 2Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding 2Sangamo BioSciences to Webcast Presentations at Investor and Analyst Briefing 2
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to current ... enables HITLAB to conduct regulated smart device and smart ... safety and research quality. "HITLAB is determined ...
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel experience and ... Over the past decade, ePassports, biometric readers, and secure ... through border control via eGates and Automated Passport Control ... and land borders across the globe. ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... offering. One major trend emerging in ... Multimodal biometric systems utilize more than one characteristic of ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... in Spanish . , In future, climate change ... in the concentration of CO 2 in the atmosphere. However, ... physiology of barley plants and increases its tolerance to salinity. This ... defended at the University of the Basque Country (UPV/EHU). Barley ...
... Early laboratory research has shown that resveratrol, a common ... most types of breast cancer, suggesting a potential role for ... substance found in red wine and red grapes. It is ... major drug stores. "Resveratrol has the ability to ...
... Men who develop breast cancer are often not treated ... treatment becomes difficult, new results show. Although most ... 1% of cases, Dr. Marina Garassino from the Orion ... organized by the European Society for Medical Oncology. ...
Cached Biology News:CO2 increase in the atmosphere augments tolerance of barley to salinity 2CO2 increase in the atmosphere augments tolerance of barley to salinity 3CO2 increase in the atmosphere augments tolerance of barley to salinity 4Researchers identify cancer preventive properties in common vitamin supplement 2Treatment delays result in poor outcomes for men with breast cancer 2
... Corning single use spatulas have been ... samples. They are for those interested in ... reusable spatulas. Each spatula is individually packaged, ... CLS number is a new product number, ...
... The LV Series offers high performance ... 14, 17, 23, and 34 frame sizes. ... perfect for life science applications, including medical ... other miniature automation systems., Meets a ...
... kit for a single fragment based screening project: , ... , 96 shape-diverse mixtures of 4 (5 ... files for structure refinement , Individual compounds ... are at ca. 50 mM. Supplied in 5 96-well trays. ...
... the proven features of the pET, BacVector ... all of the benefits and versatility of ... The pTriEx vectors have been extensively tested ... all three expression systems. In each case, ...
Biology Products: